Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Deloitte
Healthtrust
Colorcon
Boehringer Ingelheim
Federal Trade Commission
Daiichi Sankyo
Moodys
Dow
Chinese Patent Office

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,251,910

« Back to Dashboard

Which drugs does patent 6,251,910 protect, and when does it expire?

Patent 6,251,910 protects BRILINTA and is included in one NDA.

This patent has forty-four patent family members in thirty-four countries.
Summary for Patent: 6,251,910
Title: 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Abstract:Compounds of formula having the following stereochemistry ##STR1## wherein R, R.sup.1, R.sub.2, R.sup.3 and R.sup.4 are as defined in the specification. The compounds are useful as P.sub.2T receptor antagonists.
Inventor(s): Guile; Simon (Loughborough, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (Nottingham, GB)
Assignee: AstraZeneca UK Limited (London, GB)
Application Number:09/155,023
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 6,251,910

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-002 Sep 3, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms BRILINTA ticagrelor TABLET;ORAL 022433-001 Jul 20, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,251,910

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9702773Jul 22, 1997
PCT Information
PCT FiledJuly 15, 1998PCT Application Number:PCT/SE98/01393
PCT Publication Date:February 04, 1999PCT Publication Number: WO99/05143

International Patents Family Members for US Patent 6,251,910

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 0996621 ➤ Subscribe
Sweden 9702775 ➤ Subscribe
Sweden 9702773 ➤ Subscribe
Saudi Arabia 1153 ➤ Subscribe
Russian Federation 2225407 ➤ Subscribe
Portugal 996621 ➤ Subscribe
Poland 200325 ➤ Subscribe
Poland 338516 ➤ Subscribe
New Zealand 502381 ➤ Subscribe
Norway 315854 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
QuintilesIMS
Fish and Richardson
Healthtrust
Cerilliant
Deloitte
McKesson
Novartis
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot